0 CHECKOUT

Discovery Stage Partnering Terms and Agreements 2010-2015

  • ID: 650934
  • December 2015
  • Region: Global
  • 3286 Pages
  • CurrentPartnering
1 of 4

The Discovery Stage Partnering Terms and Agreements 2010-2015 report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 3,000 links to online copies of actual discovery stage deals and contract documents as submitted to the Securities READ MORE >

Note: Product cover images may vary from those shown
2 of 4

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?

2.1. Introduction
2.2. The role of discovery stage partnering
2.2.1. In-licensing at discovery stage
2.2.2. Out-licensing at discovery stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into discovery stage partnering deals
2.4.1. Licensors reasons for entering discovery stage deals
2.4.2. Licensees reasons for entering discovery stage deals
2.5. The future of discovery stage partnering deals

Chapter 3 - Discovery stage deal strategies and structure

3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical/biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study: LEO Pharma - 4SC
3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
3.2.1.1.c. Case study: Incyte - Agenus Bio
3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study: Servier - GeNeuro
3.2.2.1.b. Case study: Teva - Xenon Pharmaceuticals
3.2.2.1.c. Case study: AstraZeneca - Ardelyx
3.2.2.1.d. Case study: Baxter - Onconova Therapeutics
3.3. Early and later stage partnering - a risk/cost comparison
3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure licensing agreements
3.6.1.a. Case study : Pfizer - Spark Therapeutics
3.6.1.b. Case study : Contrafect - Trellis Bioscience
3.7. Multicomponent discovery stage partnering agreements
3.7.1.a. Example multicomponent early stage clauses
3.7.1.a. Case study: Tracon -Boehringer Ingelheim - Macrogenics
3.7.1.b. Case study: Fibrocell Science - Intrexon

Chapter 4 - Discovery stage partnering payment strategies

4.1. Introduction
4.2. Discovery stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments

Chapter 5 - Trends in discovery stage deal making

5.1. Introduction
5.2. Discovery stage partnering over the years
5.2.1.. Attributes of discovery deals
5.3. Big pharma discovery stage dealmaking activity
5.4. Big biotech discovery stage dealmaking activity
5.5. Discovery stage partnering by deal type
5.6. Discovery stage partnering by disease type
5.7. Discovery stage partnering by technology type

Chapter 6 - Average payment terms for discovery stage partnering

6.1. Introduction
6.2. Guidelines for discovery stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Discovery stage payment terms - deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Discovery stage headline values
6.4.2. Discovery stage upfront values
6.4.3. Discovery stage milestone payments
6.4.4. Discovery stage royalty rates

Chapter 7 - Leading discovery stage deals

7.1. Introduction
7.2. Top discovery stage deals by value

Chapter 8 - Big pharma and big biotech discovery stage partnering deals

8.1. Introduction
8.2. How to use big pharma/big biotech discovery stage partnering deals
8.3. Big pharma discovery stage partnering company profiles
8.4. Big biotech discovery stage partnering company profiles

Chapter 9 - Discovery stage partnering contracts directory

9.1. Introduction
9.2. Company A-Z
9.3. By deal type
9.4. By therapy area

Chapter 10 - Discovery stage dealmaking directory by year

10.1. Introduction
10.2. Discovery stage deals - 2010
10.3. Discovery stage deals - 2011
10.4. Discovery stage deals - 2012
10.5. Discovery stage deals - 2013
10.6. Discovery stage deals - 2014
10.7. Discovery stage deals - 2015

View the accompanying volume for:

Appendices
Introduction
Appendix 1 - Directory of discovery stage deals by company A-Z 2010-2015
Appendix 2 - Directory of discovery stage deals by deal type 2010-2015
Appendix 3 - Directory of discovery stage deals by therapy area 2010-2015
Appendix 4 - Partnering resource center
Online partnering
Partnering events
Further reading on dealmaking

Table of figures:
Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 2: Agreements signed by phase of development (2010-2015), % of all deals where stage disclosed
Figure 3: Components of the pure licensing deal structure
Figure 4: Payment options for discovery stage partnering deals
Figure 5: Issues affecting royalty rates
Figure 6: Discovery stage partnering frequency 2010-2015
Figure 7: Big pharma - top 50 - discovery stage deals 2010 to 2015
Figure 8: Big pharma discovery stage deal frequency - 2010 to 2015
Figure 9: Big biotech - top 50 - discovery stage deals 2010 to 2015
Figure 10: Big biotech discovery stage deal frequency - 2010 to 2015
Figure 11: Discovery stage partnering by deal type since 2010
Figure 12: Discovery stage partnering by disease type since 2010
Figure 13: Discovery stage partnering by technology type since 2010
Figure 14: Review of median upfront payments for discovery stage deals
Figure 15: Review of median milestone payments for discovery stage deals
Figure 16: Review of median royalty payments for discovery stage deals
Figure 17: Discovery stage deals with a headline value- 2010
Figure 18: Discovery stage deals with a headline value- 2011
Figure 19: Discovery stage deals with a headline value- 2012
Figure 20: Discovery stage deals with a headline value- 2013
Figure 21: Discovery stage deals with a headline value- 2014
Figure 22: Discovery stage deals with a headline value- 2015
Figure 23: Discovery stage deal headline value distribution, US$million
Figure 24: Summary median headline value for discovery stage of development, 2010-2015
Figure 25: Discovery stage deals with upfront payment values- 2010
Figure 26: Discovery stage deals with upfront payment values- 2011
Figure 27: Discovery stage deals with upfront payment values- 2012
Figure 28: Discovery stage deals with upfront payment values- 2013
Figure 29: Discovery stage deals with upfront payment values- 2014
Figure 30: Discovery stage deals with upfront payment values- 2015
Figure 31: Discovery stage deal upfront payment distribution, US$million
Figure 32: Summary median upfront payments discovery stage of development, 2010-2015
Figure 33: Discovery stage deals with milestone payments -2010
Figure 34: Discovery stage deals with milestone payments -2011
Figure 35: Discovery stage deals with milestone payments -2012
Figure 36: Discovery stage deals with milestone payments -2013
Figure 37: Discovery stage deals with milestone payments -2014
Figure 38: Discovery stage deals with milestone payments -2015
Figure 39: Discovery stage deal milestone distribution, US$million
Figure 40: Discovery stage deals with royalty rates, %- 2010
Figure 41: Discovery stage deals with royalty rates, %- 2011
Figure 42: Discovery stage deals with royalty rates, %- 2012
Figure 43: Discovery stage deals with royalty rates, %- 2013
Figure 44: Discovery stage deals with royalty rates, %- 2014
Figure 45: Discovery stage deals with royalty rates, %- 2015
Figure 46: Discovery stage deal royalty rate distribution, US$million
Figure 47: Summary median royalty rate for discovery stage of development, 2010-2015
Figure 48: Top discovery stage deals that exceeds $1 billion in deal value since 2010

Note: Product cover images may vary from those shown
3 of 4

Discovery Stage Partnering Terms and Agreements 2010-2015 provides the reader with the following key benefits:

- In-depth understanding of discovery stage deal trends since 2010.

- Access to headline, upfront, milestone and royalty data.

- Comprehensive access to over 3,000 discovery stage deals together with contract documents if available.

- Detailed access to actual discovery stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies.

- Analysis of the structure of discovery stage agreements with numerous real life case studies.

- Identify leading discovery stage deals by value since 2010.

- Identify the most active discovery stage dealmakers since 2010.

- Full listing of discovery stage deals by company A-Z, phase of development, deal type, therapy and technology focus.

- Understand the key deal terms companies have agreed in previous deals.

- Undertake due diligence to assess suitability of your proposed deal terms for partner companies.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

  • Quick Help: A printed copy of the report and CD ROM copy will be shipped to you. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.